Manufacturer of Controlled Substances Registration: PCAS-Nanosyn, LLC, 50950 [2014-20196]

Download as PDF 50950 Federal Register / Vol. 79, No. 165 / Tuesday, August 26, 2014 / Notices Controlled substance Schedule Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Thebaine (9333) ........................... Levo-alphacetylmethadol (9648) .. Oxymorphone (9652) ................... Noroxymorphone (9668) .............. Racemethorphan (9732) .............. Alfentanil (9737) ........................... Remifentanil (9739) ...................... Sufentanil (9740) .......................... Carfentanil (9743) ......................... Tapentadol (9780) ........................ Fentanyl (9801) ............................ II II II II II II II II II II II II II The company plans to manufacture small quantities of the listed controlled substances to make reference standards which will be distributed to their customers. Dated: August 19, 2014. Joseph T. Rannazzisi, Deputy Assistant Administrator. [FR Doc. 2014–20201 Filed 8–25–14; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE [Docket No. DEA–392] Manufacturer of Controlled Substances Registration: PCASNanosyn, LLC PCAS-Nanosyn, LLC applied to be registered as a manufacturer of certain basic classes of narcotic and non-narcotic controlled substances. The DEA grants PCAS-Nanosyn, LLC registration as a manufacturer of those controlled substances. SUPPLEMENTARY INFORMATION: By notice dated April 21, 2014, and published in the Federal Register on April 30, 2014, 79 FR 24452, PCAS-Nanosyn, LLC, 3331–B Industrial Drive, Santa Rosa, California 95403, applied to be registered as a manufacturer of certain basic classes of narcotic or non-narcotic controlled substances. No comments or objections have been received. The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823(a) and determined that the registration of PCAS-Nanosyn, LLC to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company’s maintenance of effective controls against diversion by inspecting and tkelley on DSK3SPTVN1PROD with NOTICES VerDate Mar<15>2010 21:48 Aug 25, 2014 Jkt 232001 Amphetamine (1100) .................... Methamphetamine (1105) ............ Methylphenidate (1724) ................ Phencyclidine (7471) .................... Codeine (9050) ............................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Methadone (9250) ........................ Morphine (9300) ........................... Oripavine (9330) ........................... Oxymorphone (9652) ................... Fentanyl (9801) ............................ Schedule II II II II II II II II II II II II II comments or objections have been received. The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Patheon Pharmaceuticals, Inc., to manufacture the basic class of this controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company’s maintenance of effective controls against diversion by inspecting and testing the company’s physical security systems, verifying the company’s compliance with state and local laws, and reviewing the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of Gamma Hydroxybutyric Acid (2010), a basic class of controlled substance listed in schedule I. The company plans to manufacture the listed controlled substance for distribution to its customers. Dated: August 19, 2014. Joseph T. Rannazzisi, Deputy Assistant Administrator. [FR Doc. 2014–20198 Filed 8–25–14; 8:45 am] Dated: August 19, 2014. Joseph T. Rannazzisi, Deputy Assistant Administrator. Notice of registration. SUMMARY: Controlled substance The company is a contract manufacturer. At the request of the company’s customers, it manufactures derivatives of controlled substances only in bulk form. Drug Enforcement Administration ACTION: testing the company’s physical security systems, verifying the company’s compliance with state and local laws, and reviewing the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the basic classes of narcotic and non-narcotic controlled substances listed: BILLING CODE 4410–09–P [FR Doc. 2014–20196 Filed 8–25–14; 8:45 am] DEPARTMENT OF LABOR BILLING CODE 4410–09–P Office of the Secretary DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Manufacturer of Controlled Substances Registration: Patheon Pharmaceuticals, Inc. ACTION: Notice of registration. Patheon Pharmaceuticals, Inc., applied to be registered as a manufacturer of a certain basic class of controlled substance. The DEA grants Patheon Pharmaceuticals, Inc., registration as a manufacturer of the controlled substance. SUPPLEMENTARY INFORMATION: By notice dated April 21, 2014, and published in the Federal Register on April 28, 2014, 79 FR 23373, Patheon Pharmaceuticals, Inc., 2110 E. Galbraith Road, Cincinnati, Ohio 45237, applied to be registered as a manufacturer of a certain basic class of non-narcotic controlled substance. No SUMMARY: PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 Agency Information Collection Activities; Submission for OMB Review; Comment Request; Fire Protection in Shipyard Employment Standard ACTION: Notice. The Department of Labor (DOL) is submitting the Occupational Safety and Health Administration (OSHA) sponsored information collection request (ICR) titled, ‘‘Fire Protection in Shipyard Employment Standard,’’ to the Office of Management and Budget (OMB) for review and approval for continued use, without change, in accordance with the Paperwork Reduction Act of 1995 (PRA), 44 U.S.C. 3501 et seq. Public comments on the ICR are invited. DATES: The OMB will consider all written comments that agency receives on or before September 25, 2014. ADDRESSES: A copy of this ICR with applicable supporting documentation; including a description of the likely SUMMARY: E:\FR\FM\26AUN1.SGM 26AUN1

Agencies

[Federal Register Volume 79, Number 165 (Tuesday, August 26, 2014)]
[Notices]
[Page 50950]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-20196]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Manufacturer of Controlled Substances Registration: PCAS-Nanosyn, 
LLC

ACTION: Notice of registration.

-----------------------------------------------------------------------

SUMMARY: PCAS-Nanosyn, LLC applied to be registered as a manufacturer 
of certain basic classes of narcotic and non-narcotic controlled 
substances. The DEA grants PCAS-Nanosyn, LLC registration as a 
manufacturer of those controlled substances.

SUPPLEMENTARY INFORMATION: By notice dated April 21, 2014, and 
published in the Federal Register on April 30, 2014, 79 FR 24452, PCAS-
Nanosyn, LLC, 3331-B Industrial Drive, Santa Rosa, California 95403, 
applied to be registered as a manufacturer of certain basic classes of 
narcotic or non-narcotic controlled substances. No comments or 
objections have been received.
    The Drug Enforcement Administration (DEA) has considered the 
factors in 21 U.S.C. 823(a) and determined that the registration of 
PCAS-Nanosyn, LLC to manufacture the basic classes of controlled 
substances is consistent with the public interest and with United 
States obligations under international treaties, conventions, or 
protocols in effect on May 1, 1971. The DEA investigated the company's 
maintenance of effective controls against diversion by inspecting and 
testing the company's physical security systems, verifying the 
company's compliance with state and local laws, and reviewing the 
company's background and history.
    Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 
CFR 1301.33, the above-named company is granted registration as a bulk 
manufacturer of the basic classes of narcotic and non-narcotic 
controlled substances listed:

 
------------------------------------------------------------------------
            Controlled substance                       Schedule
------------------------------------------------------------------------
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Methylphenidate (1724).....................  II
Phencyclidine (7471).......................  II
Codeine (9050).............................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Methadone (9250)...........................  II
Morphine (9300)............................  II
Oripavine (9330)...........................  II
Oxymorphone (9652).........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company is a contract manufacturer. At the request of the 
company's customers, it manufactures derivatives of controlled 
substances only in bulk form.

    Dated: August 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014-20196 Filed 8-25-14; 8:45 am]
BILLING CODE 4410-09-P